Backgrounds: It has been showed that everolimus-eluting stent (EES) is superior to paclitaxel-eluting stent (PES) in terms of major adverse cardiac event (MACE) in some trials. However, in diabetic patients, there were little data which stent is more effective and safe between EES and PES. Methods: Patients who underwent PCI with DES from January 2004 to December 2009 were prospectively enrolled. We analyzed the MACE including all-cause death, myocardial infarction (MI), and target vessel revascularization (TVR) in patients with diabetes mellitus by comparing PES with EES at 1 year after index PCI. Results: Overall, 752 (65.5%) patients received PCI with PES and the other 396 patients received PCI with EES. The baseline clinical and angiographic characteristics were similar between two groups. There were no differences in death, cardiac death, MI, target vessel revascularization, TVR, and composite MACE between two groups. Conclusions: There are no differences on cardiovascular events between the two groups.